News

Public · Published

Aurobindo Pharma Q2: Net profit rises 32.5% to Rs 1,124 crore, revenue hits record high

Aurobindo Pharma reported record quarterly revenue in the September quarter, up 23.9% year on year to Rs 10,263 crore. Net profit rose 32.5% to Rs 1,124 crore, while EBITDA, a measure of operating earnings, increased 28.5% to Rs 2,156 crore. US and European sales grew strongly.

Published:

Updated:

What happened

Aurobindo Pharma reported record quarterly revenue in the September quarter, up 23.9% year on year to Rs 10,263 crore. Net profit rose 32.5% to Rs 1,124 crore, while EBITDA, a measure of operating earnings, increased 28.5% to Rs 2,156 crore. US and European sales grew strongly.

Confirmed

Global impact / market context

Profit rose faster than revenue, and EBITDA margin, the share of sales left after operating costs, widened to 21% from 20.3%. If this pattern continues, stronger sales and cost control could lift earnings, while slower growth or higher costs could narrow that improvement.

Analyst inference

The US and Europe together generated nearly three-fourths of quarterly revenue, concentrating sales in those regions. Revenue rose 25.2% in the US and 27.5% in Europe, while formulations, the company's core drug business, and active pharmaceutical ingredients also recorded growth.

Confirmed

What to watch

  1. Watch whether US and European sales growth continues: because these regions supply nearly three-fourths of revenue, weaker demand there could directly slow company-wide sales. Analyst inference
  2. Track whether acquired businesses, existing products and new launches keep supporting US growth, and whether the company sustains record revenue and its higher operating-profit share of sales. Analyst inference
  3. Compare future profit and revenue growth: if operating costs increase faster than sales, the recent margin improvement may reverse and reduce earnings growth. Analyst inference

Evidence

  • Original source link unavailable